According to Guojin Securities' research report, AI applications are progressing from theoretical constructs to tangible realities. The cost-effectiveness of multi-omics development has surged a thousandfold, and the inaugural AI-driven drug is poised to hit the market. Obstacles related to cloud computing accessibility and data quantity and quality have been surmounted, while models are continually fortifying barriers. Consequently, the return on investment in innovative R&D is skyrocketing. This technological revolution is reshaping the pharmaceutical landscape, attracting the involvement of tech giants and prompting enterprises across the industry chain to expedite their strategic deployments. Notably, all ten major pharmaceutical giants are now engaged in AI initiatives. We hold a favorable view on leading pharmaceutical companies that are on the cusp of delivering robust product pipelines and exhibiting forward-thinking layouts.